Scholars@Duke
Tian Zhang

Tian Zhang

Adjunct Associate Professor in the Department of Medicine
Medicine, Medical Oncology
tian.zhang2@duke.edu
DUMC 103861, Durham, NC 27710
Dept of Medicine, Box 103861, Durham, NC 27710

Selected Publications

Real-World Treatment Outcomes in Patients With Ga68-PSMA-PET Positive Metastatic Hormone-Sensitive Prostate Cancer With or Without Conventional Imaging Correlates

Journal Article Clinical Genitourinary Cancer · February 1, 2026 Background Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging is highly sensitive, enabling detection of disease not visualized on conventional imaging, and leading to a new disease state: PSMA-avid/CT-negative metastatic ... Full text Cite

Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer.

Journal Article Clin Cancer Res · December 4, 2025 BACKGROUND: Immune checkpoint inhibitors (ICIs) have shown limited efficacy in unselected patients with metastatic castration-resistant prostate cancer (mCRPC). However, ICIs are approved for biomarker-defined subsets: microsatellite instability-high (MSI- ... Full text Link to item Cite

Complete response following trastuzumab-deruxtecan in a man with HER2-overexpressing metastatic, poorly differentiated scrotal carcinoma.

Journal Article Oncologist · December 1, 2025 Overexpression of human epidermal growth factor receptor 2 (HER2) has been implicated as a molecular driver of numerous solid tumor subtypes. An antibody drug conjugate (ADC) directed to HER2, trastuzumab-deruxtecan, recently gained tumor-agnostic FDA appr ... Full text Link to item Cite

Neoadjuvant pembrolizumab and tyrosine kinase inhibitor to facilitate imperative partial nephrectomy for renal cell carcinoma.

Journal Article Urol Oncol · November 21, 2025 OBJECTIVE: To describe clinical outcomes of patients who received neoadjuvant therapy for tumor downsizing to facilitate imperative partial nephrectomy (PN), including patients with a solitary kidney, bilateral complex renal masses, or chronic kidney disea ... Full text Link to item Cite

Extracranial Palliative Radiation Therapy for Renal Cell Carcinoma

Journal Article Advances in Radiation Oncology · October 1, 2025 Purpose: Symptom management is an integral component of care for patients with renal cell carcinoma (RCC). We evaluated the efficacy of radiation therapy (RT) and factors influencing symptom in an ethnically diverse patient population. Methods and Material ... Full text Cite

Clinical Outcomes of Patients With Metastatic Prostate Cancer With Microsatellite Instability Treated With Pembrolizumab.

Journal Article Clin Genitourin Cancer · October 2025 MSI-H prostate cancer is rarely encountered in clinical practice. When it is identified, pembrolizumab is a standard of care therapeutic option in the metastatic castration-resistant setting based on KEYNOTE-158, which included very few prostate cancer pat ... Full text Link to item Cite

Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update.

Journal Article J Clin Oncol · July 10, 2025 PURPOSE: To provide evidence-based recommendations for patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: An Expert Panel including patient representation completed a systematic review of the evidence and made recommendations. ... Full text Link to item Cite

Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer.

Journal Article Prostate Cancer Prostatic Dis · June 2025 Combined androgen deprivation therapy (ADT) and radiotherapy (RT) improves outcomes for intermediate and high-risk prostate cancer. Treatment intensification with abiraterone acetate/prednisone (AAP) provides additional benefit for high-risk disease. We pr ... Full text Link to item Cite

Systemic Treatment of Locally Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma.

Journal Article Cancers (Basel) · April 30, 2025 Non-clear cell renal cell carcinoma (nccRCC) represents a heterogenous group of malignancies with varying degrees of clinical aggressiveness and response to different systemic therapies. As the characterization of subtypes of nccRCC continues to evolve, it ... Full text Link to item Cite

Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial.

Journal Article Eur Urol Oncol · April 2025 BACKGROUND AND OBJECTIVE: Androgen deprivation therapy (ADT) with salvage radiation therapy (RT) improves survival for patients with prostate-specific antigen (PSA) recurrence after radical prostatectomy (RP) for prostate cancer (PC), but many patients suf ... Full text Link to item Cite

Surgical Outcomes of Radical Nephrectomy and Inferior Vena Cava Thrombectomy Following Preoperative Systemic Immunotherapy: A Propensity Score Analysis.

Journal Article Clin Genitourin Cancer · April 2025 INTRODUCTION: The impact of neoadjuvant immune checkpoint inhibitors (ICIs) on perioperative outcomes of radical nephrectomy (RN) with inferior vena cava (IVC) thrombectomy for renal cell carcinoma (RCC) remains unclear. This study aimed to assess the safe ... Full text Link to item Cite

Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.

Journal Article Urol Oncol · March 2025 Modern advances in systemic and localized therapies for patients with renal cell carcinoma (RCC) have significantly improved patients' outcomes. If disease progression occurs after initial treatment, clinicians often have multiple options for a first salva ... Full text Link to item Cite

First and Second-line Treatments in Metastatic Renal Cell Carcinoma.

Journal Article Eur Urol · February 2025 BACKGROUND AND OBJECTIVE: The treatment landscape for metastatic renal cell carcinoma (mRCC) has evolved significantly in recent years, leading to improved outcomes. The aim of this review is to provide clinicians with a practical guide for selecting first ... Full text Link to item Cite

A Review of Neoadjuvant Therapy for Localized and Locally Advanced Renal Cell Carcinoma.

Journal Article Cancers (Basel) · January 19, 2025 The introduction of vascular endothelial growth factor receptor-tyrosine kinases (VEGFR-TKIs) and immune checkpoint inhibitors (IOs) have drastically altered the treatment landscape for kidney cancer, with doublet combination immunotherapy (IO/IO or IO/VEG ... Full text Link to item Cite

Circulating immune biomarkers correlating with response in patients with metastatic renal cell carcinoma on immunotherapy.

Journal Article JCI Insight · January 7, 2025 Since multiple front-line immune checkpoint inhibitor-based (ICI-based) combinations are approved for metastatic renal cell carcinoma, biomarkers predicting for ICI responses are needed past clinical prognostication scores and transcriptome gene expression ... Full text Link to item Cite

Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024.

Journal Article Cancer · January 1, 2025 Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswe ... Full text Link to item Cite

Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma.

Journal Article Oncologist · December 6, 2024 Platinum-based chemotherapy has been the standard first-line (1L) treatment for advanced urothelial carcinoma (UC) for decades, based on the proven efficacy and established safety profiles of cisplatin- and carboplatin-based regimens. With the emergence of ... Full text Link to item Cite

Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers.

Journal Article Commun Med (Lond) · December 2, 2024 BACKGROUND: Breast and prostate tumors are known to be less responsive to immune checkpoint inhibitors (ICIs). Tissue-based tumor mutation burden (tTMB) has emerged as a predictive biomarker of response to ICIs, including in these "cold tumors". In clinica ... Full text Link to item Cite

First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study.

Journal Article Eur Urol · December 2024 BACKGROUND AND OBJECTIVE: Adjuvant pembrolizumab significantly improved overall survival (OS) in renal cell carcinoma (RCC), but real-world data on sequential treatment are scarce. We sought to evaluate the clinical outcomes of first-line (1L) systemic the ... Full text Link to item Cite

Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma.

Journal Article J Clin Oncol · November 20, 2024 Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Up ... Full text Link to item Cite

Socioeconomic and Demographic Disparities in Immunotherapy Utilization for Advanced Kidney and Bladder Cancer.

Journal Article Urol Oncol · November 2024 OBJECTIVES: Immunotherapy (IO) drugs have been increasingly utilized in locally advanced or metastatic clear cell renal cell carcinoma (ccRCC) and urothelial carcinoma of the bladder (UC). Multiple trials have demonstrated clear survival benefit, however, ... Full text Link to item Cite

Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy.

Journal Article Oncologist · October 3, 2024 BACKGROUND: Even though cytoreductive nephrectomy (CN) was once the standard of care for patients with advanced renal cell carcinoma (RCC), its role in treatment has not been well analyzed or defined in the era of immunotherapy (IO). MATERIALS AND METHODS: ... Full text Link to item Cite

Pathological Response and Outcomes in Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Immunotherapy-Based Therapies and Undergoing Deferred Cytoreductive Nephrectomy (CN).

Journal Article Clin Genitourin Cancer · October 2024 UNLABELLED: In this study we evaluated outcomes of patients with metastatic renal cell carcinoma who received immunotherapy before surgery. We found that receiving immunotherapy combinations before surgery can offer patients benefits in reducing tumor size ... Full text Link to item Cite

Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing.

Journal Article ESMO Open · September 2024 BACKGROUND: Controlled trials have consistently demonstrated the efficacy of poly(ADP-ribose) polymerase inhibitors (PARPis) in patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1 or BRCA2 alterations (BRCAalt). However, the rep ... Full text Link to item Cite

Perspectives on Neoadjuvant Clinical Trial Participation for Patients with Kidney Cancer: A Survey-Based Examination

Journal Article Kidney Cancer · August 19, 2024 Background: Kidney cancer is amongst the deadliest genitourinary malignancies. Neoadjuvant systemic therapy has the potential to improve survival and overall outcomes in select patients. Enrolling patients in trials of neoadjuvant treatment for kidney canc ... Full text Cite

Complete remission following pembrolizumab in a man with mCRPC with both microsatellite instability and BRCA2 mutation.

Journal Article Oncologist · August 5, 2024 Prostate cancer is one of the most prevalent malignancies in men. In the United States, 1 in 8 men will be diagnosed with prostate cancer in their lifetime. Specifically, studies have delved into male subgroups that present a heightened risk for prostate c ... Full text Link to item Cite

Design and Rationale of the Outcomes Database to Prospectively Assess the Changing Therapy Landscape in Renal Cell Carcinoma Registry: A Multi-institutional, Prospective Study of Patients with Metastatic Renal Cell Carcinoma.

Journal Article Eur Urol Open Sci · August 2024 INTRODUCTION AND HYPOTHESES: The Outcomes Database to prospectivelY aSSEss the changing TherapY landscape in Renal Cell Carcinoma (ODYSSEY RCC) Registry is a large, nationally representative prospective registry of patients with metastatic renal cell carci ... Full text Link to item Cite

Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma.

Journal Article J Clin Invest · May 30, 2024 BACKGROUNDMetastases are the hallmark of lethal cancer, though underlying mechanisms that drive metastatic spread to specific organs remain poorly understood. Renal cell carcinoma (RCC) is known to have distinct sites of metastases, with lung, bone, liver, ... Full text Link to item Cite

Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles.

Journal Article J Clin Invest · April 23, 2024 Molecular profiling of clear cell renal cell carcinoma (ccRCC) tumors of patients in a clinical trial has identified distinct transcriptomic signatures with predictive value, yet data in non-clear cell variants (nccRCC) are lacking. We examined the transcr ... Full text Link to item Cite

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

Journal Article New England Journal of Medicine · April 18, 2024 BACKGROUND Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was approved on the basis of a significant improvement in disease-free survival in the KEYNOTE-564 trial. Whether the results regarding overall survival from the third prespec ... Full text Cite

Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC).

Journal Article Journal of Clinical Oncology · February 1, 2024 LBA359Background: The randomized, multicenter, double-blind, phase 3 KEYNOTE-564 study (NCT03142334) showed that adjuvant pembrolizumab improved disease-free survival (DFS) compared with placebo following nephrectomy in participants (pts) with ccRCC at an ... Full text Cite

A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.

Journal Article Oncoimmunology · 2024 Ieramilimab, a humanized anti-LAG-3 monoclonal antibody, was well tolerated in combination with the anti-PD-1 antibody spartalizumab in a phase 1 study. This phase 2 study aimed to further investigate the efficacy and safety of combination treatment in pat ... Full text Link to item Cite

Association of radiographic and pathologic outcomes in patients (pts) with advanced renal cell carcinoma (RCC) with and without thrombus receiving preoperative immune checkpoint inhibitor (ICI) regimens and circulating biomarkers

Journal Article Journal of Clinical Oncology · January 1, 2024 Background: Primary RCC tumors and associated IVC thrombus have similar histology, however response to ICI is not always concordant. RCC with IVC thrombus is often difficult to manage, and perioperative ICI treatment responses remain largely unstudied. Met ... Full text Cite

Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.

Journal Article Hum Vaccin Immunother · December 15, 2023 Renal cell carcinoma (RCC), especially clear cell RCC, is generally considered an immunotherapy-responsive cancer. Recently, the prognosis for patients with locally advanced and metastatic RCC has significantly improved with the regulatory approvals of ant ... Full text Link to item Cite

Outcomes of Consolidative Nephrectomy following Primary Immunotherapy in Advanced Renal Cell Carcinoma: A Multicenter Analysis.

Conference Clin Genitourin Cancer · December 2023 BACKGROUND: To evaluate effect and outcomes of combination primary immunotherapy (IO) and nephrectomy for advanced renal cell carcinoma (RCC). METHODS: We conducted a multicenter, retrospective analysis of patients with advanced/metastatic RCC who received ... Full text Link to item Cite

Genitourinary cancers updates: highlights from ASCO 2023.

Journal Article J Hematol Oncol · November 21, 2023 Significant scientific advances in immunotherapy and targeted therapy approaches have improved clinical outcomes and increased treatment options for patients with genitourinary (GU) malignancies. We highlight the clinical trial developments released at the ... Full text Link to item Cite

Management of Metastatic Renal Clear Cell Cancer: ASCO Guideline Rapid Recommendation Update.

Journal Article J Clin Oncol · November 20, 2023 ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development proc ... Full text Link to item Cite

Special Issue Editorial: Emerging Therapies in Renal Cell Carcinoma: The Road to a Cure?

Journal Article Cancers (Basel) · November 2, 2023 In the past two decades, therapy development in the treatment of renal cell carcinoma has exploded [...]. ... Full text Link to item Cite

First-line systemic treatment options for advanced renal cell carcinoma

Chapter · November 1, 2023 The treatment of advanced clear cell renal cell carcinoma (ccRCC) has undergone significant changes over the last two decades, particularly with the development of antiangiogenic therapies, in particular vascular endothelial growth factor receptor (VEGFR) ... Full text Cite

The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer.

Journal Article Urol Oncol · October 2023 Newly approved systemic treatment options for metastatic urothelial cancer (mUC) have diversified treatments and improved responses and survival for chemotherapy refractory disease. These systemic treatments have associated toxicities which need appropriat ... Full text Link to item Cite

Toxicity Management of Systemic Kidney Cancer Therapies.

Journal Article Hematol Oncol Clin North Am · October 2023 Systemic treatments for metastatic renal cell carcinoma have expanded to include antiangiogenic agents targeting either vascular endothelial growth factor receptor, immune checkpoint inhibitors against cytotoxic T-lymphocyte antigen 4, or programmed cell d ... Full text Link to item Cite

The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer.

Journal Article Eur J Cancer · October 2023 For about a decade, poly [ADP ribose] polymerases (PARP) inhibitors have been used almost exclusively to treat tumours that are deficient in one of the BRCA genes. In advanced prostate cancer, which is largely driven by the activity of the androgen recepto ... Full text Link to item Cite

Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs.

Journal Article J Immunother Cancer · May 2023 With multiple PD-(L)1 inhibitors approved across dozens of indications by the US Food and Drug Administration, the number of patients exposed to these agents in adjuvant, first-line metastatic, second-line metastatic, and refractory treatment settings is i ... Full text Link to item Cite

First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC).

Journal Article J Immunother Cancer · March 2023 BACKGROUND: This phase 1 study evaluated PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in two clinical states of prostate cancer (PC), metastatic castration-resistant PC (mCRPC) and biochemical recurrence (BCR). METHODS: For dose escalati ... Full text Link to item Cite

End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy.

Journal Article JCO Oncol Pract · February 2023 PURPOSE: New therapies including oral anticancer agents (OAAs) have improved outcomes for patients with metastatic renal cell carcinoma (mRCC). However, little is known about the quality of end-of-life (EOL) care and systemic therapy use at EOL in patients ... Full text Link to item Cite

Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma.

Journal Article Clin Genitourin Cancer · February 2023 BACKGROUND: In patients with renal cell carcinoma (RCC) on cabozantinib, venous thromboembolism (VTE) management remains challenging due to limited safety data regarding direct oral anticoagulants (DOACs) use in conjunction with cabozantinib. We investigat ... Full text Link to item Cite

Post-irradiation intratumoral heterogeneity modulates response to immune checkpoint inhibition therapy in a murine melanoma model.

Journal Article Neoplasia · February 2023 PURPOSE: The underlying mechanism for radiation as a potentiator of immune checkpoint inhibition (ICI) is unclear. We developed a novel murine model to investigate the effects of post-irradiation intratumoral heterogeneity (ITH) on response to ICI. EXPERIM ... Full text Link to item Cite

Facts and Hopes for Immunotherapy in Renal Cell Carcinoma.

Journal Article Clin Cancer Res · December 1, 2022 Immunotherapy has made a significant impact in many tumors, including renal cell carcinoma (RCC). RCC has been known to be immunoresponsive since the cytokine era of IFNα and IL2, but only a small number of patients had durable clinical benefit. Since then ... Full text Link to item Cite

Tissue engineered cancer metastases as cancer vaccine to improve cancer immunotherapy.

Journal Article Acta Biomater · November 2022 Radiotherapy is often used to improve cancer immunotherapy outcomes. While there are both pre-clinical and clinical data supporting this approach, there are also significant challenges. One key challenge is that not all patients have tumors that can be eas ... Full text Link to item Cite

Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents.

Journal Article Clin Genitourin Cancer · October 2022 PURPOSE: In an era of rapid expansion of FDA approvals for oral anticancer agents (OAAs), it is important to understand the factors associated with survival among real-world populations, which include groups not well-represented in pivotal clinical trials ... Full text Link to item Cite

Bimodal liquid biopsy for cancer immunotherapy based on peptide engineering and nanoscale analysis.

Journal Article Biosens Bioelectron · October 1, 2022 Despite its high potential, PD-L1 expressed by tumors has not been successfully utilized as a biomarker for estimating treatment responses to immunotherapy. Circulating tumor cells (CTCs) and tumor-derived exosomes that express PD-L1 can potentially be use ... Full text Link to item Cite

Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC).

Journal Article Urology · October 2022 OBJECTIVE: To examine real-world adherence to oral anticancer agents (OAAs) and its association with outcomes among Medicare beneficiaries with metastatic renal cell carcinoma (mRCC). METHODS: SEER-Medicare retrospective cohort study of patients with metas ... Full text Link to item Cite

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.

Journal Article J Immunother Cancer · October 2022 BACKGROUND: Immunotherapy combinations including ipilimumab and nivolumab are now the standard of care for untreated metastatic renal cell carcinoma (mRCC). Biomarkers of response are lacking to predict patients who will have a favorable or unfavorable res ... Full text Open Access Link to item Cite

Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.

Journal Article J Clin Oncol · September 1, 2022 PURPOSE: To provide recommendations for the management of patients with metastatic clear cell renal cell carcinoma (ccRCC). METHODS: An Expert Panel conducted a systematic literature review to obtain evidence to guide treatment recommendations. RESULTS: Th ... Full text Link to item Cite

The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma.

Journal Article Cancers (Basel) · August 7, 2022 A lower baseline neutrophil-to-eosinophil ratio (NER) has been associated with improved responses to immune checkpoint inhibitors (ICI)-treated metastatic renal cell carcinoma (mRCC). This study investigated the decrease in NER at week 6 after ipilimumab/n ... Full text Link to item Cite

Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma.

Journal Article J Am Geriatr Soc · August 2022 BACKGROUND: Kidney cancer is the fastest-growing cancer diagnosis in the developed world. About 16% of new cases are stage IV, which has a low five-year survival rate. Many patients with metastatic renal cell carcinoma (mRCC) are older and may have mild co ... Full text Link to item Cite

Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics.

Journal Article European urology oncology · June 2022 Motivated by recent presentation of the KEYNOTE-564 interim results for adjuvant pembrolizumab in clear-cell renal cell carcinoma, we discuss concepts that can guide patient-specific decision-making in selecting individuals for whom adjuvant therapies shou ... Full text Cite

Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma.

Journal Article J Geriatr Oncol · June 2022 BACKGROUND: Dementia and cancer are both more common in adults as they age. As new cancer treatments become more popular, it is important to consider how these treatments might affect older patients. This study evaluates metastatic renal cell carcinoma (mR ... Full text Link to item Cite

Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma.

Journal Article J Geriatr Oncol · June 2022 INTRODUCTION: Oral anti-neoplastic agents (OAAs) for metastatic renal cell carcinoma (mRCC) are associated with increased cancer-specific survival. However, racial disparities in survival persist and older adults have the lowest rates of cancer-specific su ... Full text Link to item Cite

Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer.

Journal Article Prostate · May 2022 BACKGROUND: In preclinical models of prostate cancer (PC), disulfiram (DSF) reduced tumor growth only when co-administered with copper (Cu), and Cu uptake in tumors is partially regulated by androgen-receptor signaling. However, prior trials of DSF in PC u ... Full text Link to item Cite

A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.

Journal Article Prostate Cancer Prostatic Dis · April 2022 BACKGROUND: Men with progressive neuroendocrine or aggressive-variant metastatic prostate cancer (NEPC/AVPC) have a poor prognosis and limited treatment options, and immunotherapy has not been tested in such patients. METHODS: We conducted an open label si ... Full text Link to item Cite

First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape.

Journal Article Oncologist · March 4, 2022 Treatment paradigm for metastatic clear cell renal cell carcinoma (mccRCC) has changed dramatically over the recent decades. From cytokines, interleukin-2 and interferon-α to tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors, during t ... Full text Link to item Cite

A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND).

Journal Article Prostate Cancer Prostatic Dis · March 2022 BACKGROUND: Androgen deprivation therapy (ADT) and androgen receptor signaling inhibitors (ARSI) are associated with deleterious physical effects, which exercise may mitigate; however, exercise has never been studied in patients initiating treatment with A ... Full text Link to item Cite

Factors associated with the quality of end-of-life care for patients with metastatic renal cell carcinoma.

Conference Journal of Clinical Oncology · February 20, 2022 300 Background: Although oral anti-cancer agents (OAAs) have improved outcomes for patients with metastatic renal cell carcinoma (mRCC), most patients still die from the disease. High quality end-of-life (EOL) care remains a cruc ... Full text Cite

Pathologic outcomes at cytoreductive nephrectomy (CN) following immunotherapy (IO) for patients with advanced renal cell carcinoma (RCC).

Conference Journal of Clinical Oncology · February 20, 2022 334 Background: IO, either as combination therapy in the frontline or monotherapy in the second line, has improved outcomes for patients with advanced RCC. With the movement away from upfront CN, limited data are available on the ... Full text Cite

Molecular alterations across sites of metastasis in patients with renal cell carcinoma (RCC).

Conference Journal of Clinical Oncology · February 20, 2022 287 Background: RCC has a distinct pattern of metastatic spread with common sites of metastasis including the lung, bone, and liver. Less common sites include the brain, adrenal gland, and pancreas. While the pattern of metastati ... Full text Cite

Impact of neoadjuvant immune checkpoint inhibitor therapy on primary tumor size and complexity: Correlation with surgical quality and short term oncological outcomes.

Conference Journal of Clinical Oncology · February 20, 2022 390 Background:The concept of primary systemic therapy has gained increasing traction in the management of metastatic and locally advanced Renal Cell Carcinoma (RCC). Most series have evaluated the use of tyrosine-kinase inhibito ... Full text Cite

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.

Journal Article J Immunother Cancer · February 2022 BACKGROUND: Lymphocyte-activation gene 3 (LAG-3) is an inhibitory immunoreceptor that negatively regulates T-cell activation. This paper presents preclinical characterization of the LAG-3 inhibitor, ieramilimab (LAG525), and phase I data for the treatment ... Full text Link to item Cite

A Tribute to Dr Larissa Lee.

Journal Article Pract Radiat Oncol · 2022 Full text Link to item Cite

The Search for the Optimal Immunotherapy Sequencing in the Perioperative Setting of RCC

Chapter · January 1, 2022 Based on the S-TRAC study, sunitinib was approved as adjuvant therapy for high-risk renal cell carcinoma after nephrectomy; however, the role of perioperative immunotherapy is less clear. Multiple immunotherapy combinations have shown clinical benefit supe ... Full text Cite

Immunotherapy

Chapter · January 1, 2022 The standard of care for patients with renal cell carcinoma (RCC) has evolved rapidly with the development of immunotherapy. Since 2015, new immune checkpoint inhibitors (ICIs) have been approved by the US FDA, adding more options for RCC therapies. Recent ... Full text Cite

Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.

Journal Article Eur Urol Oncol · December 2021 BACKGROUND: Salvage external beam radiotherapy (RT) with androgen deprivation therapy (ADT) improves survival over RT in men with prostate cancer (PC) and rising prostate-specific antigen (PSA) levels after radical prostatectomy (RP). OBJECTIVE: To investi ... Full text Link to item Cite

Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma.

Journal Article JCO Oncol Pract · December 2021 PURPOSE: Availability of targeted oral anticancer agents (OAAs) has transformed care for patients with metastatic renal cell carcinoma (mRCC). Our objective was to identify patterns and predictors of OAA use within 12 months after mRCC was detected to unde ... Full text Link to item Cite

Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.

Journal Article Biomark Res · November 3, 2021 BACKGROUND: The identification of biomarkers to select patients with metastatic renal cell carcinoma (mRCC) most likely to respond to combination immunotherapy (IO) is needed. We sought to investigate an association of the baseline neutrophil-to-eosinophil ... Full text Link to item Cite

Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.

Journal Article Clin Lung Cancer · November 2021 INTRODUCTION: A high tumor mutational burden (TMB) (≥10 mut/Mb) has been associated with improved clinical benefit in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI) and is a tumor agnostic indication for pembrolizumab ac ... Full text Link to item Cite

Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.

Journal Article JAMA Netw Open · November 1, 2021 IMPORTANCE: Androgen deprivation therapy (ADT) has been theorized to decrease the severity of SARS-CoV-2 infection in patients with prostate cancer owing to a potential decrease in the tissue-based expression of the SARS-CoV-2 coreceptor transmembrane prot ... Full text Link to item Cite

Five Year Results of Short Course Complete Androgen Blockade With Abiraterone Acetate and LHRH Agonist for Unfavorable Intermediate and Favorable High Risk Prostate Cancer.

Conference International journal of radiation oncology, biology, physics · November 2021 Purpose/objective(s)Androgen deprivation therapy (ADT) and radiotherapy (RT) are synergistic, and the combination results in improved survival outcomes for aggressive prostate cancers. However, long-term ADT carries substantial burden of toxicity ... Full text Cite

Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.

Journal Article J Clin Oncol · October 1, 2021 PURPOSE: To evaluate the safety and efficacy of gemcitabine and cisplatin in combination with the immune checkpoint inhibitor pembrolizumab as neoadjuvant therapy before radical cystectomy (RC) in muscle-invasive bladder cancer. METHODS: Patients with clin ... Full text Link to item Cite

Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.

Journal Article JAMA Oncol · October 1, 2021 IMPORTANCE: Preclinical studies suggest that inhibition of single-stranded DNA repair by ataxia telangiectasia and Rad3 (ATR) may enhance the cytotoxicity of cisplatin, gemcitabine, and other chemotherapeutic agents. Cisplatin with gemcitabine remains the ... Full text Link to item Cite

Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.

Journal Article Cancer Med · October 2021 BACKGROUND: Improving oral anticancer agent (OAA) initiation and adherence is the important quality-of-care issues, particularly since one fourth of anticancer agents being developed will be administered orally. Our objective was to identify provider- and ... Full text Link to item Cite

Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents.

Conference Journal of Clinical Oncology · October 1, 2021 116 Background: It is important to understand how emerging new therapies, such as oral anti-cancer agents (OAAs), diffuse across and can improve outcomes within real-world populations, which include age groups and racial groups n ... Full text Cite

Combination strategies to maximize the benefits of cancer immunotherapy.

Journal Article J Hematol Oncol · September 27, 2021 Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy (ACT) have revolutionized cancer treatment, especially in patients whose disease was otherwise considered incurable. However, primary and secondary resistance to single agen ... Full text Link to item Cite

Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics.

Journal Article Neoplasia · September 2021 Abiraterone acetate (AA) has been proven effective for metastatic castration-resistant prostate cancer (mCRPC), and it has been proposed that adaptive AA may reduce toxicity and prolong time to progression, when compared to continuous AA. We developed a si ... Full text Link to item Cite

A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab.

Journal Article Target Oncol · September 2021 BACKGROUND: Bone metastases (BM) in renal cell carcinoma (RCC) patients are associated with poor outcomes. There are limited published data on outcomes in these patients with immunotherapy agents. We present a multi-institutional, retrospective analysis of ... Full text Link to item Cite

Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab.

Journal Article J Immunother Cancer · September 2021 The combination of ipilimumab plus nivolumab (I+N) has greatly improved outcomes in patients with intermediate or poor-risk untreated metastatic renal cell carcinoma (mRCC). However, little is known about the outcomes of patients with brain metastasis (BrM ... Full text Link to item Cite

A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.

Journal Article Cancer · August 15, 2021 BACKGROUND: Retrospective analyses of randomized trials suggest that Black men with metastatic castration-resistant prostate cancer (mCRPC) have longer survival than White men. The authors conducted a prospective study of abiraterone acetate plus prednison ... Full text Link to item Cite

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.

Journal Article Ann Oncol · June 2021 BACKGROUND: Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of patients with cancer and coronavirus 2019 (COVID-19) reported to the COVID-19 and ... Full text Link to item Cite

A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.

Conference Journal of Clinical Oncology · May 20, 2021 4507 Background: Cisplatin with gemcitabine (CG) remains the standard upfront chemotherapy regimen for metastatic urothelial cancer (mUC). Preclinical synergy was noted between cisplatin and berzosertib, a selective ATR inhibitor ... Full text Cite

Association of baseline neutrophil-to-eosinophil ratio (NER) and neutrophil-to-lymphocyte ratio (NLR) with response to combination immunotherapy (IO) with ipilimumab plus nivolumab (ipi/nivo) in patients with metastatic renal cell carcinoma (mRCC).

Conference Journal of Clinical Oncology · May 20, 2021 4563 Background: Previous reports have shown that the baseline neutrophil-to-lymphocyte ratio (NLR) is associated with prognosis in patients with mRCC. However, NLR has not been shown to reliably predict for response to IO. Retro ... Full text Cite

Efficacy of anti-PD(L)1 therapy for patients (Pts) with advanced urothelial carcinoma (aUC) with primary resistance to platinum-based chemotherapy (PC).

Conference Journal of Clinical Oncology · May 20, 2021 e16515 Background: PC remains standard first-line (1L) therapy for aUC. Approximately 15% of pts exhibit primary resistance (P-R) to PC and ∼25% progress by 4 months. PD(L)1 inhibitors yield objective response rates (ORR) of ∼20% ... Full text Cite

First-in-human, phase I study of PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in biochemical relapse (BCR) and metastatic castration-resistant prostate cancer (mCRPC).

Conference Journal of Clinical Oncology · May 20, 2021 2612 Background: Therapeutic vaccines targeting PC-associated antigens represent attractive approaches in combination with immune checkpoint inhibitors (ICI). Safety/antitumor activity of PF-06753512 (PrCa VBIR) was evaluated in ... Full text Cite

Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer.

Journal Article Int J Radiat Oncol Biol Phys · April 1, 2021 PURPOSE: Long-term androgen-deprivation therapy (ADT) is the standard of care in combination with radiation therapy (RT) in high-risk prostate cancer (PC), despite substantial toxicity from the resulting hypogonadism. We hypothesized that a combination of ... Full text Link to item Cite

Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.

Journal Article Cancer Med · April 2021 INTRODUCTION: Two separate antiangiogenic tyrosine kinase inhibitors (TKIs) and immunotherapy (IO) combinations are FDA-approved as front-line treatment for metastatic renal cell carcinoma (mRCC). Little is known about off-protocol and post-front-line expe ... Full text Link to item Cite

Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma diagnosed between 2008 and 2012.

Journal Article J Geriatr Oncol · March 2021 PURPOSE: Treatment of advanced urothelial carcinoma (UC) remains a challenging clinical entity occurring predominantly in older patients with limited treatment options. However, real-world treatment patterns, differential cancer center access, and associat ... Full text Link to item Cite

An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC).

Journal Article Oncologist · March 2021 We report a case using combination cabozantinib plus nivolumab to salvage disease control in a patient with refractory metastatic renal cell carcinoma. The patient had previously experienced disease progression from high-dose interleukin-2, sunitinib, pazo ... Full text Link to item Cite

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.

Journal Article J Immunother Cancer · March 2021 BACKGROUND: Low-density lipoprotein receptor-related protein 1b (encoded by LRP1B) is a putative tumor suppressor, and preliminary evidence suggests LRP1B-mutated cancers may have improved outcomes with immune checkpoint inhibitors (ICI). METHODS: We condu ... Full text Open Access Link to item Cite

Control of renal cell carcinoma brain metastases with cabozantinib following progression on immune checkpoint inhibitor therapy

Journal Article Current Problems in Cancer Case Reports · March 1, 2021 Patients with metastatic renal cell carcinoma are often affected by metastases to the brain that result in significant complications as well as limitations in clinical trial participation. Early generation tyrosine-kinase inhibitor and immune checkpoint in ... Full text Cite

COVID-19 vaccines for patients with cancer: benefits likely outweigh risks.

Journal Article J Hematol Oncol · February 27, 2021 Less than a year since the start of the COVID-19 pandemic, ten vaccines against SARS-CoV-2 have been approved for at least limited use, with over sixty others in clinical trials. This swift achievement has generated excitement and arrives at a time of grea ... Full text Link to item Cite

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.

Journal Article Lancet · February 20, 2021 BACKGROUND: MET (also known as hepatocyte growth factor receptor) signalling is a key driver of papillary renal cell carcinoma (PRCC). Given that no optimal therapy for metastatic PRCC exists, we aimed to compare an existing standard of care, sunitinib, wi ... Full text Link to item Cite

Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).

Conference Journal of Clinical Oncology · February 20, 2021 90 Background: ADT with salvage RT improves survival for men with PSA recurrence after RP. Current standard duration of ADT for high risk PSA recurrence is up to 2 years with RT; therefore shortening but intensifying systemic the ... Full text Cite

Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.

Conference Journal of Clinical Oncology · February 20, 2021 270 Background: MET signaling is a key molecular driver in pRCC. Given that there is no optimal therapy for metastatic pRCC, we sought to compare an existing standard (sunitinib) to putative MET kinase inhibitors. Methods: Eligib ... Full text Cite

ASSET: Alternative schedule sunitinib in metastatic renal cell carcinoma (RCC)—Cardiopulmonary exercise testing (CPET).

Conference Journal of Clinical Oncology · February 20, 2021 300 Background: Sunitinib (SUN) is a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) approved for treatment of advanced RCC and high risk RCC after nephrectomy. Evidence suggests that a 2 week (wk) on, 1 ... Full text Cite

Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy prior to radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC).

Conference Journal of Clinical Oncology · February 20, 2021 396 Background: Cisplatin-based neoadjuvant chemotherapy is standard of care in MIBC with improved pathologic response and overall survival (OS) compared to RC alone. Pembrolizumab (pembro) is active in high-risk non-muscle invas ... Full text Cite

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Conference Journal of Clinical Oncology · February 20, 2021 TPS366 Background: First-line treatment of mRCC has rapidly changed to include IPI-NIVO or CABO, with clinical benefit of each based on the Checkmate 214 and CABOSUN (A031203) trials. Combination immunotherapy with VEGF therapies ... Full text Cite

Oral anticancer agent (OAA) adherence and survival in elderly patients with metastatic renal cell carcinoma (mRCC).

Conference Journal of Clinical Oncology · February 20, 2021 280 Background: Multiple effective oral anticancer agents (OAAs) are now approved for the treatment of patients with advanced or metastatic renal cell carcinoma (mRCC) based on improvement in overall and progression-free survival ... Full text Cite

Efficacy of the PD-L1 inhibitor avelumab in neuroendocrine or aggressive variant prostate cancer: Results from a phase II, single-arm study.

Conference Journal of Clinical Oncology · February 20, 2021 89 Background: Men with metastatic neuroendocrine/small cell and aggressive variant prostate cancer (NEPC/AVPC) have poor outcomes despite platinum and taxane chemotherapy. These tumors share common features with small cell lung ... Full text Cite

Severe-COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT).

Conference Journal of Clinical Oncology · February 20, 2021 39 Background: The presence of progressing cancer, male sex and advanced age have been shown to increase the severity of coronavirus disease 2019 (COVID-19). Given that the androgen regulated gene TMPRSS2 has been implicated in S ... Full text Cite

Angiogenic and T-effector subgroups identified by gene expression profiling (GEP) and propensity for PBRM1 and BAP1 alterations in clear cell renal cell carcinoma (ccRCC).

Conference Journal of Clinical Oncology · February 20, 2021 343 Background: With the emergence of multiple active treatment options in RCC, predictive biomarkers for optimal treatment selection are lacking. Gene expression data from IMmotion151 and Javelin Renal 101 clinical trials genera ... Full text Cite

Evaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC).

Conference Journal of Clinical Oncology · February 20, 2021 291 Background: Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer. Despite cabo improving RCC outcomes, VTE management in these patients remains a challenge, partly due to poor understandin ... Full text Cite

Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer.

Journal Article Biomark Res · February 18, 2021 BACKGROUND: A subset of men with metastatic prostate cancer (mPC) responds to immune checkpoint inhibitors, and there is an unmet need to predict those most likely to benefit. We characterized circulating tumor cells (CTCs) for expression of immune checkpo ... Full text Link to item Cite

Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy.

Journal Article Clin Cancer Res · January 1, 2021 Subset analysis of patients with sarcomatoid renal cell carcinoma (sRCC) included in the CheckMate 214 trial of ipilimumab-nivolumab versus sunitinib showed improved outcomes in sRCC with ipilimumab-nivolumab. The use of checkpoint inhibitor-based regimens ... Full text Link to item Cite

Early Bone Metastases are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma.

Journal Article Bladder Cancer · 2021 BACKGROUND: Outcomes of patients with metastatic urothelial carcinoma (mUC) with early bone metastases (eBM) vs no early bone metastases (nBM) have not thoroughly been described in the age of immuno-oncology. OBJECTIVE: To compare survival and other clinic ... Full text Link to item Cite

Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States.

Journal Article Kidney Cancer · 2021 BACKGROUND: Substantial racial and socioeconomic disparities in metastatic RCC (mRCC) have persisted following the introduction of targeted oral anticancer agents (OAAs). The relationship between patient characteristics and OAA access and costs that may un ... Full text Link to item Cite

A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance.

Journal Article Cancer Cell · December 14, 2020 When the COVID-19 pandemic began, formal frameworks to collect data about affected patients were lacking. The COVID-19 and Cancer Consortium (CCC19) was formed to collect granular data on patients with cancer and COVID-19 at scale and as rapidly as possibl ... Full text Open Access Link to item Cite

PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.

Journal Article Clin Genitourin Cancer · December 2020 BACKGROUND: Immune checkpoint inhibitors are now standard of care for many patients with metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC). Given real-world limitations in programmed death-ligand 1 (PD-L1) testing, concordanc ... Full text Link to item Cite

The Immunotherapy Landscape in Renal Cell Carcinoma.

Journal Article BioDrugs · December 2020 The past 30 years have borne witness to a gradual evolution in the treatment landscape of advanced renal cell carcinoma (aRCC). Early immunotherapy approaches such as interferon-α and high-dose interleukin-2 (IL-2) therapy in this immunogenic tumor provide ... Full text Link to item Cite

Novel therapies are changing treatment paradigms in metastatic prostate cancer.

Journal Article J Hematol Oncol · October 28, 2020 Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose polymerase (PARP) inhibitors for patients w ... Full text Link to item Cite

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.

Journal Article Cancer · October 15, 2020 BACKGROUND: Inhibition of the programmed cell death protein 1 (PD-1) pathway has demonstrated clinical benefit in metastatic urothelial cancer (mUC); however, response rates of 15% to 26% highlight the need for more effective therapies. Bruton tyrosine kin ... Full text Open Access Link to item Cite

Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application.

Journal Article Biosens Bioelectron · August 15, 2020 Sensitive detection of circulating tumor cells (CTCs) from patients' peripheral blood facilitates on-demand monitoring of tumor progression. However, clinically significant capture of renal cell carcinoma CTCs (RCC-CTCs) remains elusive due to their hetero ... Full text Link to item Cite

Abstract 6439: CapioCyte™ technology for efficient capture and downstream analysis of circulating tumor cells from renal cell carcinoma

Conference Cancer Research · August 15, 2020 AbstractObjective:The objective of this work was to obtain highly sensitive purification and post-capture analysis of renal cell carcinoma (RCC) circulating tumor cells (CTCs ... Full text Cite

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

Journal Article Lancet · June 20, 2020 BACKGROUND: Data on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness. METHODS: In this cohort s ... Full text Link to item Cite

Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.

Journal Article Oncoimmunology · June 10, 2020 BACKGROUND: Biomarkers predicting immunotherapy response in metastatic renal cell cancer (mRCC) are lacking. PD-L1 immunohistochemistry is a complementary diagnostic for immune checkpoint inhibitors (ICIs) in mRCC, but has shown minimal clinical utility an ... Full text Link to item Cite

Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer.

Journal Article Bioorg Med Chem Lett · June 1, 2020 Disulfiram in conjunction with copper has been shown to be a potent anticancer agent. However, disulfiram's therapeutic potential in prostate cancer is hindered by off-target effects due to its reactive and nucleophilic thiol-containing component, diethyld ... Full text Link to item Cite

Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation.

Journal Article Nat Commun · April 9, 2020 Intermittent androgen deprivation therapy (IADT) is an attractive treatment for biochemically recurrent prostate cancer (PCa), whereby cycling treatment on and off can reduce cumulative dose and limit toxicities. We simulate prostate-specific antigen (PSA) ... Full text Link to item Cite

Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.

Journal Article J Immunother Cancer · March 2020 BACKGROUND: Immune checkpoint inhibitors (ICIs) have expanded treatment options for metastatic renal cell carcinoma (mRCC); however, there are limited predictive biomarkers for response to ICIs in this indication, with programmed death-ligand 1 (PD-L1) sta ... Full text Link to item Cite

WOMENtorship: The #WomenInMedicine perspective.

Journal Article Med Teach · February 2020 Mentorship is essential for career development, personal development, and job satisfaction for physicians in academic medicine. Women in academic medicine face unique challenges including significant gender disparities in positions of leadership as well as ... Full text Link to item Cite

Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer.

Journal Article Clin Genitourin Cancer · February 2020 Many therapeutic options are now available for men with metastatic castration-resistant prostate cancer (mCRPC), including next-generation androgen receptor axis-targeted therapies (AATTs), immunotherapy, chemotherapy, and radioisotope therapies. No clear ... Full text Link to item Cite

Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.

Journal Article Cancer J · 2020 PURPOSE: In recent years, the treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) have expanded significantly. In addition to androgen deprivation therapy, the systemic treatments now include docetaxel, abiraterone, enzalutamide, and ... Full text Link to item Cite

The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma.

Journal Article Cancer Treat Res Commun · 2020 Since the approval of immunotherapy checkpoint inhibitors for first-line treatment of metastatic renal cell carcinoma, new and clinically relevant questions have emerged that ongoing clinical trials and trials in development will address. These questions i ... Full text Link to item Cite

The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer: What Have We Learned and How Will It Inform Future Adjuvant Trials.

Journal Article Cancer J · 2020 The primary treatment for localized renal cell carcinoma (RCC) is surgical resection with curative intent. Despite this, many patients, especially those with high-risk features, will develop recurrent or metastatic disease. Antiangiogenic therapies targeti ... Full text Link to item Cite

Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer.

Journal Article JCO Precis Oncol · 2020 PURPOSE: Androgen receptor splice variant 7 (AR-V7) detection in circulating tumor cells (CTCs) is associated with a low probability of response and short progression-free (PFS) and overall survival (OS) in men with metastatic castration-resistant prostate ... Full text Link to item Cite

CLINICAL TRIALS IN PROGRESS

Journal Article ONCOLOGY-NEW YORK · 2020 Cite

Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer.

Journal Article Urol Oncol · November 2019 PURPOSE: Targeted inhibitors and immunotherapy have entered the treatment landscape of metastatic prostate cancer. Genomic testing may uncover which patients benefit most from these therapies. We report the clinical utility and benefits of FoundationOne te ... Full text Link to item Cite

Biologically Targeted Photo-Crosslinkable Nanopatch to Prevent Postsurgical Peritoneal Adhesion.

Journal Article Adv Sci (Weinh) · October 2, 2019 Peritoneal adhesion occurs in a majority of patients following abdominal surgery and can result in significant side effects and complications. Current strategies to minimize adhesions involve the use of nontargeted anatomical barriers that are either ineff ... Full text Link to item Cite

Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients.

Journal Article J Oral Pathol Med · September 2019 BACKGROUND: Since the inhibitory immune checkpoint receptors have been described to benefit the OSCC patients clinically, it is unknown that whether their expression in tumor immune microenvironment (TME) can determine the clinical outcome in response to n ... Full text Link to item Cite

Multitargeted Nanoparticles Deliver Synergistic Drugs across the Blood-Brain Barrier to Brain Metastases of Triple Negative Breast Cancer Cells and Tumor-Associated Macrophages.

Journal Article Adv Healthc Mater · September 2019 Patients with brain metastases of triple negative breast cancer (TNBC) have a poor prognosis owing to the lack of targeted therapies, the aggressive nature of TNBC, and the presence of the blood-brain barrier (BBB) that blocks penetration of most drugs. Ad ... Full text Link to item Cite

Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.

Journal Article Cancer Med · August 2019 BACKGROUND: Pembrolizumab is approved for patients with metastatic, microsatellite instability (MSI)-high or mismatch repair-deficient (dMMR) solid tumors. However, very few men with prostate cancer were included in these initial studies. METHODS: We perfo ... Full text Link to item Cite

Abstract CT162: Pembrolizumab monotherapy for the adjuvant treatment of renal cell carcinoma post-nephrectomy: Randomized, double-blind, Phase III KEYNOTE-564 study

Conference Cancer Research · July 1, 2019 AbstractBackground: Typical management for renal cell carcinoma (RCC) is nephrectomy. However, patients with intermediate- to high-risk advanced disease can experience relapse. Upregulation of the program ... Full text Cite

Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.

Journal Article Clin Genitourin Cancer · June 2019 The incidence of renal-cell carcinoma has been increasing each year, with nearly one third of new cases diagnosed at advanced or metastatic stage. The advent of targeted therapies for metastatic renal-cell carcinoma (mRCC) has underscored the need to subty ... Full text Link to item Cite

Emerging therapeutic targets for patients with advanced prostate cancer.

Journal Article Cancer Treat Rev · June 2019 Although recent advances in the treatment of castration-resistant prostate cancer (CRPC) have significantly improved patient outcomes, advanced prostate cancer is still associated with substantial morbidity and mortality, particularly in patients who devel ... Full text Link to item Cite

Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).

Conference Journal of Clinical Oncology · May 20, 2019 e16079 Background: ICIs have revolutionized treatment for mRCC; however there are limited predictive biomarkers for response to ICIs. PD-L1 status is still controversial, demonstrating little predictive utility in mRCC. TMB is pr ... Full text Cite

A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR).

Conference Journal of Clinical Oncology · May 20, 2019 TPS5097 Background: Androgen deprivation combined with salvage external beam radiation therapy (RT) have improved survival for patients (pts) with non-metastatic hormone naïve PC and PSA recurrence after radical prostatectomy (RP ... Full text Cite

Immune checkpoint inhibitor response in tumors with LRP1B variants.

Conference Journal of Clinical Oncology · May 20, 2019 e14291 Background: Low-density lipoprotein receptor-related protein 1B (LRP1B) is a putative tumor suppressor gene spanning > 500 kb on chromosome 2. A melanoma study previously reported enrichment of LRP1B mutations in respon ... Full text Cite

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).

Conference Journal of Clinical Oncology · May 20, 2019 2595 Background: ICIs are now standard of care for mRCC; however, there are few biomarkers to predict ICI response. Recent data from atezolizumab/bevacizumab trials in mRCC suggest tumors with high Teff Full text Cite

PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Conference Journal of Clinical Oncology · May 20, 2019 TPS4596 Background: First-line treatment of mRCC has rapidly changed to include IPI-NIVO or CABO, with clinical benefit of each based on the Checkmate 214 and CABOSUN trials. Combination immunotherapy with VEGF therapies have sho ... Full text Cite

Prevalence of pathogenic germline variants in DNA repair by race, age, and ethnicity in men with prostate cancer.

Conference Journal of Clinical Oncology · May 20, 2019 5062 Background: Patients with advanced prostate cancer (PC) frequently harbor pathogenic or likely pathogenic (P/LP) germline variants (GVs) in mismatch repair (MMR) and homologous repair (HR) enzymes which have clinical and tre ... Full text Cite

Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).

Conference Journal of Clinical Oncology · May 20, 2019 e14259 Background: Immune checkpoint inhibitors (ICIs) are standard of care for mRCC and mUC patients (pts). PD-L1 status is gaining importance as a predictive biomarker, particularly for cisplatin-ineligible mUC. PD-L1 positivit ... Full text Cite

Optimizing Advances in Nanoparticle Delivery for Cancer Immunotherapy.

Journal Article Adv Drug Deliv Rev · April 2019 Cancer immunotherapy is one of the fastest growing and most promising fields in clinical oncology. T-cell checkpoint inhibitors are revolutionizing the management of advanced cancers including non-small cell lung cancer and melanoma. Unfortunately, many co ... Full text Link to item Cite

Cell proliferation as a biomarker for response to immune checkpoint inhibitors in highly inflamed renal cell carcinoma.

Conference Journal of Clinical Oncology · March 10, 2019 61 Background: Cell proliferation is an important marker of survival in many tumors and we hypothesized that this attribute could be related to response to immune checkpoint inhibitors in RCC. Previously we reported (SITC 2018) m ... Full text Cite

Cell proliferation as a biomarker for response to immune checkpoint inhibitors in PD-L1 negative renal cell carcinoma.

Conference Journal of Clinical Oncology · March 10, 2019 62 Background: Cell proliferation is an important marker of survival in many tumors, and we hypothesized that this attribute could be related to response to immune checkpoint inhibitors (ICIs) in RCC. Previously we reported (SITC ... Full text Cite

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).

Conference Journal of Clinical Oncology · March 10, 2019 63 Background: ICIs are now standard of care for mRCC; however, there are few biomarkers to predict ICI response. Recent data from atezolizumab/bevacizumab trials in mRCC suggest tumors with high Teff Full text Cite

Multidimensional flow characterization of circulating immune cells in cisplatin-resistant metastatic urothelial cancer (mUC) patients (pts) treated with pembrolizumab (P) with or without acalabrutinib (acala).

Conference Journal of Clinical Oncology · March 1, 2019 357 Background: Immunotherapy checkpoint inhibitors (ICIs) are now standard treatments (txs) in mUC, with response rates ranging 15-25%. A phase 2 randomized study (NCT02351739) treated 75 pts with mUC with either P or PA. We pro ... Full text Cite

Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).

Conference Journal of Clinical Oncology · March 1, 2019 589 Background: ICIs have revolutionized treatment for mRCC; however there are limited predictive biomarkers for response to ICIs. PD-L1 status is still controversial demonstrating little predictive utility in mRCC. TMB is predic ... Full text Cite

Characterization of genomic alterations as biomarkers of immune checkpoint inhibitor (ICI) response in metastatic urothelial carcinoma (mUC).

Conference Journal of Clinical Oncology · March 1, 2019 400 Background: ICIs have expanded therapeutic options for mUC patients (pts); however, biomarkers such as PD-L1 have not served as reliable predictors of treatment efficacy. High tumor mutation burden (TMB) has been previously d ... Full text Cite

Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).

Conference Journal of Clinical Oncology · March 1, 2019 577 Background: Immune checkpoint inhibitors (ICIs) are now standard of care for mRCC and mUC patients (pts). PD-L1 status is gaining importance as a predictive biomarker, particularly for cisplatin-ineligible mUC. Four different ... Full text Cite

Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC).

Conference Journal of Clinical Oncology · March 1, 2019 172 Background: Pembrolizumab is approved for patients with metastatic, microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors who have progressed on prior therapy and have no satisfactory treatm ... Full text Cite

PEAX: Men with metastatic castrate-resistant prostate cancer (mCRPC) treated with either sipuleucel-T (SIP-T), enzalutamide (ENZA) or abiraterone acetate (ABI) undergoing cardiopulmonary exercise testing (CPET).

Conference Journal of Clinical Oncology · March 1, 2019 281 Background: Both ENZA and ABI are associated with significant toxicity to the cardiovascular-musculoskeletal system and physical side effects. However whether they cause a decline in cardiorespiratory fitness (CRF), as conven ... Full text Cite

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).

Conference Journal of Clinical Oncology · March 1, 2019 607 Background: ICIs are now standard of care for mRCC; however, there are few biomarkers to predict ICI response. Recent data from atezolizumab/bevacizumab trials in mRCC suggest tumors with high Teff Full text Cite

Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): The STREAM trial.

Conference Journal of Clinical Oncology · March 1, 2019 29 Background: Salvage external beam radiotherapy (RT) and hormonal therapy improves survival over RT alone in men with non-metastatic hormone naïve PC and PSA recurrence after radical prostatectomy (RP). We investigated the safe ... Full text Cite

Precision Medicine Approaches When Prostate Cancer Akts Up.

Journal Article Clin Cancer Res · February 1, 2019 Ipatasertib combined with abiraterone in PTEN-null prostate cancer improved progression-free survival in a randomized phase II study of patients with metastatic castration-resistant prostate cancer (mCRPC), providing clinical evidence of reciprocal activat ... Full text Link to item Cite

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.

Journal Article J Immunother Cancer · February 1, 2019 BACKGROUND: Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression independent of major ICI targets (e.g., PD-1). Clinical experience with response prediction based on PD-L1 expression suggests that other factors influ ... Full text Link to item Cite

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.

Journal Article J Immunother Cancer · January 24, 2019 BACKGROUND: PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies used for PD-L1 IHC, each developed with a diffe ... Full text Link to item Cite

Cancer of the Kidney

Chapter · January 1, 2019 Renal cell carcinoma (RCC) accounts for approximately 4% of adult malignancies, including approximately 90% of primary renal tumors. RCC exists in sporadic and hereditary forms and is a clinically and pathologically heterogeneous disease. The WHO classific ... Full text Cite

Urologic Malignancies

Chapter · January 1, 2019 Immune checkpoint inhibitors (ICI) have revolutionized the care of urologic malignancies, in particular urothelial carcinoma (UC) and renal cell carcinoma (RCC). Five PD-1/PD-L1 ICIs have been approved for platinum-refractory advanced UC: atezolizumab, pem ... Full text Cite

In Situ Proapoptotic Peptide-Generating Rapeseed Protein-Based Nanocomplexes Synergize Chemotherapy for Cathepsin-B Overexpressing Breast Cancer.

Journal Article ACS Appl Mater Interfaces · December 5, 2018 Intracellular activation of nanomaterials within cancer cells presents a powerful means to enhance anticancer specificity and efficacy. In light of upregulated lysosomal protease cathepsin-B (CathB) in many types of invasive cancer cells, herein, we exploi ... Full text Link to item Cite

The promise of immunotherapy in genitourinary malignancies.

Journal Article Precis Clin Med · December 2018 A broad understanding of the tumor immune landscape has led to a revolution of immune checkpoint inhibitors in the treatment of multiple cancer types. In genitourinary malignancies, immune checkpoint inhibitors have improved outcomes for patients with meta ... Full text Link to item Cite

Can oral chemotherapy parity laws reduce patients’ out-of-pocket (OOP) costs?

Conference Journal of Clinical Oncology · October 20, 2018 97 Background: Insurance plans vary coverage for infusional (IV) vs oral drugs, leading some to suggest that patients on oral drugs pay more OOP than those on IV drugs. 43 states have passed laws requiring insurers to cover oral ... Full text Cite

Leveraging γ-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells.

Journal Article Angew Chem Int Ed Engl · September 24, 2018 A prodrug approach is presented to direct copper-dependent cytotoxicity to prostate cancer cells. The prochelator GGTDTC requires activation by γ-glutamyl transferase (GGT) to release the metal chelator diethyldithiocarbamate from a linker that masks its t ... Full text Link to item Cite

Abstract B038: Convergent hormone therapy resistance mediated by stress/dormancy-like pathways in prostate cancer

Conference Cancer Research · August 15, 2018 AbstractBackground: Novel agents that inhibit the androgen receptor (AR), including abiraterone acetate and enzalutamide, have significantly prolonged life in many men with metastatic castration-resistant pr ... Full text Cite

Abstract 5702: Characterization of circulating tumor cells during immune checkpoint inhibition in metastatic renal cell carcinoma and malignant melanoma

Conference Cancer Research · July 1, 2018 AbstractBackground: Although immune checkpoint inhibitors (ICIs) have shown efficacy in a range of solid tumors, there are no established circulating biomarkers able to identify early responders to treatment ... Full text Cite

Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture.

Journal Article Clin Cancer Res · June 1, 2018 Purpose: We aimed to examine the effects of multivalent binding and biomimetic cell rolling on the sensitivity and specificity of circulating tumor cell (CTC) capture. We also investigated the clinical significance of CTCs and their kinetic profiles in pat ... Full text Link to item Cite

Organ-specific metastases obtained by culturing colorectal cancer cells on tissue-specific decellularized scaffolds.

Journal Article Nat Biomed Eng · June 2018 Metastatic disease remains the primary cause of mortality in cancer patients. Yet the number of available in vitro models to study metastasis is limited by challenges in the recapitulation of the metastatic microenvironment in vitro, and by difficulties in ... Full text Link to item Cite

Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy - an illustration with firsthand examples.

Journal Article Acta Pharmacol Sin · May 2018 Nanotechnology has been applied extensively in drug delivery to improve the therapeutic outcomes of various diseases. Tremendous efforts have been focused on the development of novel nanoparticles and delineation of the physicochemical properties of nanopa ... Full text Link to item Cite

Platinum sensitivity in metastatic prostate cancer: does histology matter?

Journal Article Prostate Cancer Prostatic Dis · April 2018 BACKGROUND: Platinum-based chemotherapy is effective in men with neuroendocrine prostate cancer (NEPC), but it is unclear whether histology (adenocarcinoma vs. non-adenocarcinoma NEPC variants) is predictive of platinum sensitivity. Given that NEPC exists ... Full text Link to item Cite

Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer.

Conference Journal of Clinical Oncology · February 20, 2018 11 Background: Combined external beam radiotherapy (RT) and androgen deprivation therapy (ADT) improves survival over RT alone for high risk prostate cancer (PC). Long-term ADT use, currently recommended for high risk PC, also in ... Full text Cite

Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer (mPC).

Conference Journal of Clinical Oncology · February 20, 2018 191 Background: Most immune checkpoint inhibitors have shown limited efficacy in unselected men with mPC, and there is limited understanding about which immune checkpoints (ICs) are relevant in mPC. We evaluated ICs on the cell s ... Full text Cite

Clinical utility of non-EpCAM based circulating tumor cell assays.

Journal Article Adv Drug Deliv Rev · February 1, 2018 Methods enabling the isolation, detection, and characterization of circulating tumor cells (CTCs) in blood have clear potential to facilitate precision medicine approaches in patients with cancer, not only for prognostic purposes but also for prediction of ... Full text Link to item Cite

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.

Journal Article J Immunother Cancer · January 29, 2018 BACKGROUND: Nivolumab is approved for patients with metastatic renal cell carcinoma (mRCC) refractory to prior antiangiogenic therapy. The clinical activity of nivolumab in patients with non-clear cell RCC subtypes remains unknown as these patients were ex ... Full text Open Access Link to item Cite

Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.

Journal Article J Immunother Cancer · January 25, 2018 Immune checkpoint inhibitors targeting the PD-1 pathway have greatly changed clinical management of metastatic urothelial carcinoma and metastatic renal cell carcinoma. However, response rates are low, and biomarkers are needed to predict for treatment res ... Full text Open Access Link to item Cite

Organ-specific metastases obtained by culturing colorectal cancer cells on tissue-specific decellularized scaffolds.

Journal Article Nat Biomed Eng · 2018 Metastatic disease remains the primary cause of mortality in cancer patients. Yet the number of available in vitro models to study metastasis is limited by challenges in the recapitulation of the metastatic microenvironment in vitro, and by difficulties in ... Link to item Cite

Effects of acylation and glycation treatments on physicochemical and gelation properties of rapeseed protein isolate

Journal Article Rsc Advances · January 1, 2018 The aim of this study was to improve the gelation property of rapeseed protein isolates (RPI) by means of acylation and glycation. The results showed that acylation and glycation within RPI occurred at Lys, and Lys, Met, Ile, Leu and Pro, respectively. Acy ... Full text Cite

The clinical significance of c-Kit mutations in metastatic oral mucosal melanoma in China.

Journal Article Oncotarget · October 10, 2017 c-Kit mutations are frequently detected in mucosal melanomas, but their clinical significance in metastatic oral mucosal melanomas (OMM) remains unclear. The main purpose of this study was to investigate the clinical and pathological features of metastatic ... Full text Link to item Cite

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice.

Journal Article J Vis Exp · October 5, 2017 Combination chemotherapy is frequently used in the clinic for cancer treatment; however, associated adverse effects to normal tissue may limit its therapeutic benefit. Nanoparticle-based drug combination has been shown to mitigate the problems encountered ... Full text Link to item Cite

Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy.

Journal Article Nat Nanotechnol · September 2017 Immunotherapy holds tremendous promise for improving cancer treatment. To administer radiotherapy with immunotherapy has been shown to improve immune responses and can elicit the 'abscopal effect'. Unfortunately, response rates for this strategy remain low ... Full text Link to item Cite

Prostate cancer targeted prodrug based on copper prochelator

Conference ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY · August 20, 2017 Link to item Cite

Targeted prodrugs to manipulate copper biology of prostate cancer

Conference ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY · August 20, 2017 Link to item Cite

Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer.

Journal Article Urol Oncol · June 2017 PURPOSE: Evidence suggests differences in androgen receptor AR signaling between black (B) and white (W) patients with prostate cancer, but pivotal trials of abiraterone acetate (AA) for patients with metastatic castration-resistant prostate cancer (mCRPC) ... Full text Link to item Cite

Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.

Journal Article Acta Pharmacol Sin · June 2017 Lung metastasis is the major cause of death in patients with triple negative breast cancer (TNBC), an aggressive subtype of breast cancer with no effective therapy at present. It has been proposed that dual-targeted therapy, ie, targeting chemotherapeutic ... Full text Link to item Cite

Cabozantinib in genitourinary malignancies.

Journal Article Future Oncol · April 2017 Cabozantinib inhibits a variety of cellular receptors including VEGFR1-3, MET, AXL, RET, FLT3 and KIT. These signaling pathways have been shown to be important in genitourinary malignancies. Along its clinical development, it has shown most activity in adv ... Full text Link to item Cite

Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer.

Journal Article Nanomedicine · April 2017 The combination chemotherapy regimen of cisplatin (CP) and docetaxel (DTX) is effective against a variety of cancers. However, combination therapies present unique challenges that can complicate clinical application, such as increases in toxicity and impre ... Full text Link to item Cite

Blood-brain barrier-penetrating amphiphilic polymer nanoparticles deliver docetaxel for the treatment of brain metastases of triple negative breast cancer.

Journal Article J Control Release · January 28, 2017 Brain metastasis is a fatal disease with limited treatment options and very short survival. Although systemic chemotherapy has some effect on peripheral metastases of breast cancer, it is ineffective in treating brain metastasis due largely to the blood-br ... Full text Link to item Cite

Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials.

Journal Article Wiley Interdiscip Rev Nanomed Nanobiotechnol · January 2017 Nanomedicine is a relatively new field that is rapidly evolving. Formulation of drugs on the nanoscale imparts many physical and biological advantages. Such advantages can in turn translate into improved therapeutic efficacy and reduced toxicity. While app ... Full text Link to item Cite

Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma.

Journal Article Am Soc Clin Oncol Educ Book · 2017 Treatment options for metastatic clear cell renal cell carcinoma (ccRCC) have evolved markedly over the past decade, with multiple targeted therapies approved for the disease. In contrast, little improvement has been made in the management of metastatic no ... Full text Link to item Cite

Ki67 proliferation index as a histopathological predictive and prognostic parameter of oral mucosal melanoma in patients without distant metastases

Journal Article Journal of Cancer · January 1, 2017 Background: To investigate the relationship between clinical and histopathological characteristics and overall survival of patients with oral mucosal melanoma (OMM) without distal metastasis in order to provide predictive prognostic information of OMM. Met ... Full text Cite

Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies.

Journal Article Urol Oncol · November 2016 BACKGROUND: The therapeutic armamentarium for metastatic renal cell carcinoma has rapidly expanded over the past decade to include a number of anti-angiogenic therapies and more recently, an immunotherapy. Biomarkers in the peripheral circulation are easil ... Full text Link to item Cite

Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy.

Journal Article Int J Radiat Oncol Biol Phys · November 1, 2016 PURPOSE: To examine the effect of radiation on in vitro drug activation and release of Promitil, a pegylated liposomal formulation of a mitomycin C (MMC) lipid-based prodrug; and examine the efficacy and toxicity of Promitil with concurrent radiation in co ... Full text Link to item Cite

Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma.

Journal Article Asian J Urol · October 2016 The treatment of metastatic renal cell carcinoma (RCC) and urothelial carcinoma (UC) remains a major challenge. Past research has implicated the immune system in tumor surveillance of both malignancies, leading to the application of immunotherapy agents fo ... Full text Link to item Cite

Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer.

Journal Article Oncotarget · August 2, 2016 Treatment with androgen-targeted therapies can induce upregulation of epithelial plasticity pathways. Epithelial plasticity is known to be important for metastatic dissemination and therapeutic resistance. The goal of this study is to elucidate the functio ... Full text Open Access Link to item Cite

Is Advanced Imaging in Early-Stage Breast Cancer Ever Warranted? Reconciling Clinical Judgment With Common Quality Measures.

Journal Article J Natl Compr Canc Netw · August 2016 BACKGROUND: The American Board of Internal Medicine Foundation's Choosing Wisely initiative aims to reduce unnecessary advanced imaging for early-stage breast cancer (ESBC). Additionally, NCCN Clinical Practice Guidelines in Oncology for Breast Cancer perm ... Full text Link to item Cite

What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence.

Journal Article Ther Adv Urol · August 2016 Prostate cancer is the most common cancer in men and the second most deadly. About one-third of patients with prostate cancer will develop metastatic disease. We discuss the six United States Food and Drug Administration (FDA) approved treatments for metas ... Full text Link to item Cite

Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor.

Journal Article Nanomedicine · July 2016 UNLABELLED: Effective combination chemotherapy requires the delivery of drugs of synergism to tumor sites while sparing normal tissues. Herein we investigated whether coencapsulation of doxorubicin and mitomycin C within polymer-lipid hybrid nanoparticles ... Full text Link to item Cite

Development of a Novel c-MET-Based CTC Detection Platform.

Journal Article Mol Cancer Res · June 2016 UNLABELLED: Amplification of the MET oncogene is associated with poor prognosis, metastatic dissemination, and drug resistance in many malignancies. We developed a method to capture and characterize circulating tumor cells (CTC) expressing c-MET using a fe ... Full text Open Access Link to item Cite

Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic.

Journal Article Biomaterials · March 2016 Zoledronate (Zol) is a third-generation bisphosphonate that is widely used as an anti-resorptive agent for the treatment of cancer bone metastasis. While there is preclinical data indicating that bisphosphonates such as Zol have direct cytotoxic effects on ... Full text Link to item Cite

A role for the androgen receptor in the treatment of male breast cancer.

Journal Article Crit Rev Oncol Hematol · February 2016 Male breast cancer (BC) is relatively rare, making up less than 1% of all breast cancer cases in the United States. Treatment guidelines for male BC are derived from studies on the treatment of female BC, and are based molecular and clinical characteristic ... Full text Link to item Cite

Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer.

Journal Article Curr Oncol Rep · January 2016 Men with metastatic castration-resistant prostate cancer (mCRPC) frequently have circulating tumor cells (CTCs) that are detectable in their peripheral blood. The CellSearch® method of enumerating CTCs is presently the only FDA-cleared CTC test available c ... Full text Link to item Cite

Comparison of Quality Oncology Practice Initiative (QOPI) Measure Adherence Between Oncology Fellows, Advanced Practice Providers, and Attending Physicians.

Journal Article J Cancer Educ · December 2015 Quality improvement measures are uniformly applied to all oncology providers, regardless of their roles. Little is known about differences in adherence to these measures between oncology fellows, advance practice providers (APP), and attending physicians. ... Full text Link to item Cite

Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch.

Journal Article Clin Cancer Res · October 15, 2015 Notch signaling is implicated in prostate cancer progression and docetaxel resistance. Cui and colleagues describe the additive efficacy and mechanisms of a γ-secretase inhibitor, PF-03084014, and docetaxel in preclinical models of prostate cancer, suggest ... Full text Open Access Link to item Cite

Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.

Journal Article Clin Genitourin Cancer · August 2015 BACKGROUND: Abiraterone acetate (AA) has demonstrated improved outcomes in men with metastatic castration-resistant prostate cancer (mCRPC). However, data are lacking on the effect of AA on subsequent efficacy of enzalutamide or docetaxel. PATIENTS AND MET ... Full text Link to item Cite

Abstract 1847: AR-V7 regulation during epithelial plasticity

Conference Cancer Research · August 1, 2015 AbstractBackground: The androgen receptor (AR) is a key gene involved in prostate cancer (PC) biology, including disease development, response to initial hormonal therapies, and subsequent resistance to horm ... Full text Cite

Mismatch repair gone awry: Management of Lynch syndrome.

Journal Article Crit Rev Oncol Hematol · March 2015 The hallmark of Lynch syndrome involves germline mutations of genes important in DNA mismatch repair. Affected family kindreds will have multiple associated malignancies, the most common of which is colorectal adenocarcinoma. Recently, evidence has shown t ... Full text Link to item Cite

Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.

Journal Article Expert Opin Pharmacother · March 2015 INTRODUCTION: Over the past decade, treatment options for men with metastatic castration-resistant prostate cancer (CRPC) have expanded with the addition of abiraterone acetate (AA), enzalutamide, sipuleucel-T, radium-223, docetaxel and cabazitaxel. The op ... Full text Link to item Cite

Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal malignancies.

Conference Journal of Clinical Oncology · January 20, 2015 84 Background: Multiple GI malignancies including gastric, pancreatic, and colorectal cancers harbor genetic alterations in the MET oncogene. MET amplification is associated with poor prognosis, and c-MET targeted therapies are i ... Full text Cite

Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes.

Journal Article J Natl Compr Canc Netw · May 2014 Neuroendocrine prostate cancer (NEPC) encompasses various clinical contexts, ranging from the de novo presentation of small cell prostatic carcinoma to a treatment-emergent transformed phenotype that arises from typical adenocarcinoma of the prostate. The ... Full text Link to item Cite

Standardizing and Evaluating Transitions of Care in the Era of Duty Hour Reform: One Institution's Resident-Led Effort.

Journal Article J Grad Med Educ · December 2013 BACKGROUND: Compliance with the Accreditation Council for Graduate Medical Education duty hour standards may necessitate more frequent transitions of patient responsibility. INTERVENTION: We created a multidisciplinary Patient Safety and Quality Council wi ... Full text Open Access Link to item Cite

Clinical phenotypes of castration-resistant prostate cancer.

Journal Article Clin Adv Hematol Oncol · November 2013 Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that no longer responds to androgen deprivation therapy. At the genome level, CRPC is a heterogeneous disease that is marked by a range of genetic and epigenetic lesions. These lesio ... Link to item Cite

PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions.

Journal Article AJR Am J Roentgenol · November 2013 OBJECTIVE: Hypoxia is a characteristic of many tumors and portends a worse prognosis in lung, cervical, prostate, and rectal cancers. Unlike the others, lung cancers present a unique challenge in measuring hypoxia, with invasive biopsies and higher rates o ... Full text Link to item Cite

Biochemical failure in prostate cancer

Chapter · July 1, 2013 Prostate cancer treatment failure after local therapy can be detected through changes in PSA prior to any clinical evidence of disease. Therefore, posttreatment elevation, also called biochemical failure, has been utilized as a surrogate for disease recurr ... Full text Cite

Prevalence and impact of correlative science in breast cancer phase II trials.

Journal Article Breast Cancer Res Treat · June 2013 Correlative science (CS) can potentially augment clinical trial results by identifying biomarkers of response and resistance to a novel intervention. We evaluated recently published breast cancer phase II trials (BP2T) to determine prevalence, characterist ... Full text Link to item Cite

Handoffs in the era of duty hours reform: a focused review and strategy to address changes in the Accreditation Council for Graduate Medical Education Common Program Requirements.

Journal Article Acad Med · April 2012 With changes in the Accreditation Council for Graduate Medical Education (ACGME) Common Program Requirements related to transitions in care effective July 1, 2011, sponsoring institutions and training programs must develop a common structure for transition ... Full text Link to item Cite

Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis.

Journal Article Biomaterials · November 2011 Peritoneal metastasis is a major cause of morbidity and mortality in ovarian cancer. While intraperitoneal chemotherapy and radiotherapy have shown favorable clinical results, both are limited by their non-targeted nature. We aimed to develop a biologicall ... Full text Link to item Cite

Outcomes in phase II trials of metastatic breast cancer: Where is the bar?

Conference Journal of Clinical Oncology · May 20, 2011 Full text Cite

Pharmaceutical involvement in phase II breast cancer clinical trials.

Conference Journal of Clinical Oncology · May 20, 2011 Full text Cite

The role of biologic therapy in phase II breast cancer clinical trials.

Conference Journal of Clinical Oncology · May 20, 2011 Full text Cite

Outcomes in phase II trials of metastatic breast cancer: Where is the bar?

Journal Article J Clin Oncol · May 20, 2011 2590 Background: Phase II trials serve to provide safety and efficacy data for evaluating novel interventions that may be selected for large Phase III trials. To help define benchmarks for efficacy, we evaluated outcomes of all recently published metastati ... Link to item Cite

Pharmaceutical involvement in phase II breast cancer clinical trials.

Journal Article J Clin Oncol · May 20, 2011 6104 Background: Pharmaceutical industry (PHI) involvement in breast cancer clinical trials is increasing and may correlate with positive outcomes. We sought to further investigate the prevalence and potential impact of PHI involvement in breast cancer res ... Link to item Cite

Prevalence and impact of correlative science in breast cancer phase II trials.

Journal Article J Clin Oncol · May 20, 2011 1046 Background: Correlative science (CS) can augment clinical trial results by identifying biomarkers of response and resistance to a novel intervention. There is little data on how frequently CS is included in breast cancer phase II trials (BP2T). We eva ... Link to item Cite

The role of biologic therapy in phase II breast cancer clinical trials.

Journal Article J Clin Oncol · May 20, 2011 e13048 Background: Molecularly-targeted biologics (BioRx) hold the promise of improving outcomes and reducing toxicity of breast cancer therapy. We evaluated outcomes and trial characteristics of recently published breast cancer phase II trials (BCT) compa ... Link to item Cite